NKG2D-DARIC T-cells

N/A

Report date: 2025/01/26 15:12:19

Base Information

Drug NameNKG2D-DARIC T-cells

Drug Alias Nameanti-NKG2D-ligand CAR T-cell therapy (bluebird bio)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionNKG2D ligands modulators

TargetsNKG2D ligands

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGenetix Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A